J Smolen

Summary

Country: Austria

Publications

  1. pmc Consensus statement on the use of rituximab in patients with rheumatoid arthritis
    J S Smolen
    Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:143-50. 2007
  2. pmc Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
    Mahboob U Rahman
    Centocor R and D, Inc, Malvern, Pennsylvania, USA
    Ann Rheum Dis 70:1631-40. 2011
  3. pmc Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    Maya H Buch
    Section of Musculoskeletal Diseases, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 70:909-20. 2011
  4. ncbi request reprint EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 73:492-509. 2014
  5. doi request reprint Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
    Lancet 381:918-29. 2013
  6. pmc Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
    Josef S Smolen
    Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 72:482-92. 2013
  7. ncbi request reprint Treat-to-target: rationale and strategies
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria
    Clin Exp Rheumatol 30:S2-6. 2012
  8. doi request reprint Forget personalised medicine and focus on abating disease activity
    Josef S Smolen
    2nd Department of Medicine, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 72:3-6. 2013
  9. doi request reprint Rituximab in psoriatic arthritis: an exploratory evaluation
    Esther Jimenez-Boj
    Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 71:1868-71. 2012
  10. pmc Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
    Josef S Smolen
    Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria
    Ann Rheum Dis 71:1671-9. 2012

Collaborators

Detail Information

Publications151 found, 100 shown here

  1. pmc Consensus statement on the use of rituximab in patients with rheumatoid arthritis
    J S Smolen
    Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:143-50. 2007
    ..The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis...
  2. pmc Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
    Mahboob U Rahman
    Centocor R and D, Inc, Malvern, Pennsylvania, USA
    Ann Rheum Dis 70:1631-40. 2011
    ..To evaluate changes in baseline patient characteristics and entry criteria of randomised, controlled studies of tumour necrosis factor alpha (TNFα) inhibitors in rheumatoid arthritis (RA) patients...
  3. pmc Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    Maya H Buch
    Section of Musculoskeletal Diseases, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 70:909-20. 2011
    ..Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA...
  4. ncbi request reprint EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 73:492-509. 2014
    ..They are based on evidence and expert opinion and intended to improve outcome in patients with RA. ..
  5. doi request reprint Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
    Lancet 381:918-29. 2013
    ..The aim of the PRESERVE trial was to assess whether low disease activity would be sustained with reduced doses or withdrawal of etanercept in patients with moderately active disease...
  6. pmc Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
    Josef S Smolen
    Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 72:482-92. 2013
    ..This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion...
  7. ncbi request reprint Treat-to-target: rationale and strategies
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria
    Clin Exp Rheumatol 30:S2-6. 2012
    ..The background of the treat-to-target concept and future aspects are discussed...
  8. doi request reprint Forget personalised medicine and focus on abating disease activity
    Josef S Smolen
    2nd Department of Medicine, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 72:3-6. 2013
    ..Until then, the focus of clinicians may have to solely rest on clinical disease activity assessment and targeting remission or low disease activity rapidly...
  9. doi request reprint Rituximab in psoriatic arthritis: an exploratory evaluation
    Esther Jimenez-Boj
    Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 71:1868-71. 2012
    ..RTX is effective in autoantibody positive RA patients, although some efficacy has been reported in seronegative individuals. RTX has not yet been assessed in PsA. Therefore, an open label study of RTX in PsA was performed...
  10. pmc Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
    Josef S Smolen
    Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria
    Ann Rheum Dis 71:1671-9. 2012
    ..The aim of this study was to assess long-term golimumab therapy in patients with rheumatoid arthritis (RA) who discontinued previous tumour necrosis factor alpha (TNFα) inhibitor(s) for any reason...
  11. pmc Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 71:687-93. 2012
    ..Such disassociation of disease activity and structural damage has not been shown for biological agents other than TNF-i...
  12. pmc Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Theresa Kapral
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 9:R72. 2007
    ..However, reduced joint counts are appropriate and valid tools for formal disease activity assessment, such as done in composite indices...
  13. pmc The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
    ..Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab...
  14. pmc Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
    Theresa Kapral
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:R46. 2006
    ..Re-employment of MTX despite prior inefficacy, but not re-employment of other DMARDs, is an effective therapeutic option, especially in those patients in whom the methotrexate dose of the original course was low...
  15. pmc Impairment of chondrocyte biosynthetic activity by exposure to 3-tesla high-field magnetic resonance imaging is temporary
    Ilse Gerlinde Sunk
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria ilse
    Arthritis Res Ther 8:R106. 2006
    ..Although this decrease in biosynthetic activity seems to be transient, articular cartilage exposed to high-energy EMF may become vulnerable to damage...
  16. pmc Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R796-806. 2005
    ..e. the sum of tender and swollen joint counts [28 joints] and patient and physician global assessments [in cm]) - would have comparable validity in clinical cohorts...
  17. doi request reprint Activity assessments in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Curr Opin Rheumatol 20:306-13. 2008
    ..the importance of assessing disease activity in general, aiming for significant improvement particularly low disease activity and remission, and the value of employing simplified instruments toward this end in rheumatoid arthritis..
  18. ncbi request reprint The burden of rheumatoid arthritis and access to treatment: a medical overview
    J Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 8:S39-47. 2008
    ..Therapeutic outcome can be predicted by clinical means...
  19. ncbi request reprint Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    J S Smolen
    Department of Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 68:823-7. 2009
    ..To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab...
  20. pmc Combating the burden of musculoskeletal conditions
    J S Smolen
    Department of Internal Medicine III, Medical University Vienna and Lainz Hospital, Vienna, Austria
    Ann Rheum Dis 63:329. 2004
  21. ncbi request reprint What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials
    Josef S Smolen
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    J Rheumatol Suppl 79:15-20. 2007
    ..The safety profile of these therapies shows that infusion reactions and infections are the most commonly reported important adverse events. Premedication with corticosteroids reduces the infusion reactions to rituximab...
  22. ncbi request reprint Autoimmunity and rheumatoid arthritis
    J S Smolen
    Medical University Vienna
    Autoimmun Rev 3:S23. 2004
  23. ncbi request reprint New therapies for treatment of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 370:1861-74. 2007
    ..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented...
  24. ncbi request reprint The need for new classification criteria for rheumatoid arthritis
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 52:3333-6. 2005
  25. ncbi request reprint What should be our treatment goal in rheumatoid arthritis today?
    J S Smolen
    Department of Rheumatology, Medical University of Vienna Second Department of Medicine, Lainz Hospital, Vienna, Austria
    Clin Exp Rheumatol 24:S-7-13. 2006
    ....
  26. ncbi request reprint Therapeutic strategies in early rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Best Pract Res Clin Rheumatol 19:163-77. 2005
    ..Whether a 'window of opportunity' exists during which effective therapy might lead to cure is still an open issue and will be the focus of clinical trials in the near future...
  27. ncbi request reprint Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomi
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 52:1020-30. 2005
    ..To assess the relationship between inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment...
  28. pmc Interleukin-6: a new therapeutic target
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:S5. 2006
    ..Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate...
  29. pmc Expanding the frontiers of therapy
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:S1. 2006
  30. doi request reprint Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Ann Rheum Dis 68:1535-40. 2009
    ....
  31. doi request reprint Does damage cause inflammation? Revisiting the link between joint damage and inflammation
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 68:159-62. 2009
    ..However, the clinical evidence for this relationship is still to be provided as proof of the concept...
  32. ncbi request reprint Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants
    Josef S Smolen
    Medical University of Vienna and Hietzing Hospital, Vienna, Austria
    Arthritis Rheum 63:43-52. 2011
    ..To determine the effects of tocilizumab on rheumatoid arthritis (RA) disease activity and remission assessment, using measures that do or do not comprise acute-phase reactants...
  33. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
    ....
  34. doi request reprint Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants
    Josef S Smolen
    Department of Medicine III, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
    Arthritis Rheum 63:43-52. 2011
    ..To determine the effects of tocilizumab on rheumatoid arthritis (RA) disease activity and remission assessment, using measures that do or do not comprise acute-phase reactants...
  35. ncbi request reprint A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    J S Smolen
    University of Vienna and Lainz Hospital, Austria
    Rheumatology (Oxford) 42:244-57. 2003
    ..The objective of this study was to verify the usefulness of a simple disease activity index (SDAI) for rheumatoid arthritis (RA)...
  36. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  37. doi request reprint Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:1058-64. 2010
    ..Joint damage is an important outcome in trials of rheumatoid arthritis (RA), usually assessed by Total Sharp Score (TSS). It is currently unknown how it translates numerically into disability by the Health Assessment Questionnaire (HAQ)...
  38. doi request reprint Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
    Josef S Smolen
    Medical University of Vienna and Hietzing Hospital, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
    Lancet 374:210-21. 2009
    ..We assess the efficacy and safety of the TNFalpha inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFalpha inhibitors...
  39. pmc Infliximab: 12 years of experience
    Josef S Smolen
    Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 13:S2. 2011
    ..With our current understanding, substantial data and increasing confidence regarding use in practice, infliximab can be considered a well-known drug in our continued campaign against inflammatory rheumatic diseases...
  40. pmc Developments in the clinical understanding of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 11:204. 2009
    ..Finally, with the advent of novel therapies, remission has become a reality and the treatment algorithms encompassing all of the above-mentioned aspects will allow us to achieve the rigorous aspirations of today and tomorrow...
  41. ncbi request reprint Therapeutic strategies for rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Nat Rev Drug Discov 2:473-88. 2003
    ....
  42. pmc Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
    J Smolen
    Department of Internal Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Austria
    Ann Rheum Dis 68:797-804. 2009
    ..Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor...
  43. ncbi request reprint Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice
    G Schett
    Department of Internal Medicine III, University of Vienna, Austria
    Arthritis Rheum 44:2888-98. 2001
    ....
  44. ncbi request reprint The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
    ....
  45. doi request reprint Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 371:987-97. 2008
    ..Our aim was to assess the therapeutic effects of blocking interleukin 6 by inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis...
  46. ncbi request reprint Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus
    G Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna Medical School, Vienna, Austria
    Rheumatology (Oxford) 40:424-31. 2001
    ..Anti-erythropoietin antibodies are frequently present in SLE and interfere with the measurement of serum erythropoietin level. However, these antibodies are not associated with increased severity of SLE-associated anaemia...
  47. ncbi request reprint Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Int Arch Allergy Immunol 122:279-86. 2000
    ..Whether such autoantibodies are recurrently produced in patients with Schnitzler's syndrome and play a role in the pathophysiology of the disease remains to be determined...
  48. pmc Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis
    G Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 61:463-7. 2002
  49. pmc Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
    M Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 66:1059-65. 2007
    ..In rheumatoid arthritis (RA), treatment with disease-modifying antirheumatic drugs (DMARDs) frequently needs to be changed because of insufficient effectiveness...
  50. ncbi request reprint DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 21:S169-73. 2003
    ..By contrast to changes in DMARD usage, survey data show neither a shortening of referral time nor a change in the approach to diagnose early RA. These data indicate a need for more dissemination of the early arthritis concept...
  51. ncbi request reprint A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures
    J S Smolen
    University of Vienna and Krankenhaus Lainz, Division of Rheumatology, Internal Medicine III, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 21:S209-10. 2003
  52. doi request reprint Patient perspective of hand osteoarthritis in relation to concepts covered by instruments measuring functioning: a qualitative European multicentre study
    T Stamm
    Vienna Medical University, Department of Internal Medicine III, Division of Rheumatology, Wahringer Gurtel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 68:1453-60. 2009
    ..To explore whether the concepts important to patients with hand osteoarthritis (OA) are covered by the most commonly used instruments measuring functioning...
  53. doi request reprint Life stories of people with rheumatoid arthritis who retired early: how gender and other contextual factors shaped their everyday activities, including paid work
    T A Stamm
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Musculoskeletal Care 8:78-86. 2010
    ..The aim of the present study was to explore how contextual factors affect the everyday activities of women and men with rheumatoid arthritis (RA), as evident in their life stories...
  54. pmc Chondrocyte number and proteoglycan synthesis in the aging and osteoarthritic human articular cartilage
    K Bobacz
    Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 63:1618-22. 2004
    ..To correlate the number of chondrocytes in healthy and osteoarthritic human articular cartilage with age, and to evaluate the influence of donor age on total proteoglycan synthesis...
  55. pmc The stressed synovium
    G Schett
    Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1180 Vienna, Austria
    Arthritis Res 3:80-6. 2001
    ..Stress signalling pathways are therefore new and promising targets of future anti-rheumatic therapies...
  56. ncbi request reprint Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report
    M Brunner
    Internal Medicine I, University of Vienna Medical School, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 46:1580-4. 2002
    ..Her pulmonary function has returned to normal. Although a longer followup is required for assessment of the durability of response, the patient's course indicates that ASCT may be a way to reinduce tolerance in patients with SLE...
  57. doi request reprint [Ankylosing spondylitis in Central and Eastern Europe. Cross-sectional study on treatment modalities, disease activity and quality of life]
    W Ebner
    Medical Department II, Rheumatology, Hietzing Hospital, Wolkersbergenstr 1, 1130, Wien, Osterreich
    Z Rheumatol 67:503-10. 2008
    ....
  58. pmc Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
    J Wolf
    Second Department of Medicine, Lainz Hospital, Wolkersbergenstr 1, A 1130 Vienna, Austria
    Ann Rheum Dis 64:564-8. 2005
    ..Transport proteins may affect the therapeutic efficacy of this drug in patients with rheumatoid arthritis...
  59. doi request reprint Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1242-9. 2009
    ..The aim of this study was to evaluate whether there is a latency in the effect of disease activity on radiographic progression in patients with RA...
  60. ncbi request reprint Assessing remission in clinical practice
    M Mierau
    2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
    Rheumatology (Oxford) 46:975-9. 2007
    ..We aimed at evaluating sustained remission in a large cohort of patients followed prospectively in clinical practice and to evaluate available instruments to define remission for their stringency in defining this state...
  61. ncbi request reprint Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
    K P Machold
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 46:342-9. 2007
    ..This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA (<or=3 months after onset of symptoms)...
  62. ncbi request reprint The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheumatology (Oxford) 45:1133-9. 2006
    ..To investigate the perception of values of individual core set measures by rheumatologists, and how it differs across measures and across physicians...
  63. pmc Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 62:944-51. 2003
    ..To determine the survival and clinical effectiveness of leflunomide (LEF) compared with methotrexate (MTX) and sulfasalazine (SSZ) for RA in an observational study...
  64. ncbi request reprint Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme
    G F Wiesinger
    Department of Physical Medicine and Rehabilitation, University of Vienna, Austria
    Br J Rheumatol 37:196-200. 1998
    ..Besides medication, a physical training programme consisting mainly of concentric muscle contractions should therefore be an integral part of therapy, particularly in view of the cardiopulmonary risk of these patients...
  65. ncbi request reprint The Austrian Early Arthritis Registry
    K P Machold
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Clin Exp Rheumatol 21:S113-7. 2003
    ....
  66. ncbi request reprint Remission of rheumatoid arthritis: should we care about definitions?
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 24:S-45-51. 2006
    ..All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard...
  67. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1360-4. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  68. ncbi request reprint One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle?
    W B Graninger
    Department of Medicine, Division of Rheumatology, Department of Internal Medicine III, Vienna General Hospital, University of Vienna, Vienna, Austria
    Curr Opin Rheumatol 13:209-13. 2001
    ..In addition to the necessity of understanding the pathogenic events proximal to TNF-alpha induction, pharmacologic intervention with small molecules in the TNF signaling pathways may constitute a promising strategy...
  69. ncbi request reprint The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 41:1367-74. 2002
    ..This study aimed to reveal treatment patterns with traditional DMARDs and their changes during the two decades before the recent introduction of new DMARDs...
  70. ncbi request reprint Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis
    T Stranzl
    Division of Oncology, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 21:27-32. 2003
    ..The aim of the present study was to determine the impact of FPGS mRNA expression on resistance to methotrexate therapy in patients with rheumatoid arthritis (RA)...
  71. doi request reprint A1.24 Cilengitide reduces pannus formation and bone erosions in collagen induced arthritis
    D Sykoutri
    Department of Rheumatology, Medical University of Vienna
    Ann Rheum Dis 73:A10. 2014
    ..We aimed to further characterise the effect of cilengitide in arthritis...
  72. doi request reprint A1.80 Alterations in gait profile and bone marrow inflammation before the onset of collagen-induced arthritis
    K Sinn
    Medical University of Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
    Ann Rheum Dis 73:A35. 2014
    ..Chronic inflammation of joints ulimatively leads to bone and cartilage damage resulting in functional impairment or even complete disabilities of joints in RA patients...
  73. ncbi request reprint Is pro-matrix metalloproteinase-3 a marker for posttraumatic cartilage degradation?
    K Bobacz
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Vienna, Austria
    Osteoarthritis Cartilage 11:665-72. 2003
    ..In this study we investigated the significance of pro-matrixmetalloproteinase-3 (proMMP-3) for this purpose...
  74. ncbi request reprint Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus
    W Füreder
    Department of Internal Medicine I, University of Vienna, Austria
    Lupus 11:221-6. 2002
    ..01), but thrombopoietin levels were not significantly different. Taken together, thrombopoietin levels are significantly higher in the sera of SLE patients than in healthy controls and anti-thrombopoietin antibodies are frequently found...
  75. doi request reprint Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study
    V Nell-Duxneuner
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, A 1090 Vienna, Austria
    Ann Rheum Dis 69:169-74. 2010
    ..To investigate time courses of autoantibody profiles in patients with early arthritis...
  76. pmc Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 62:482-6. 2003
    ..The progression of rheumatoid arthritis (RA) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, toxicity limits their use...
  77. pmc Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 63:1269-75. 2004
    ..To determine if rheumatologists have changed their views on diagnosis and treatment of early rheumatoid arthritis (RA)...
  78. pmc Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells
    J Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 63:1632-7. 2004
    ....
  79. pmc Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 61:630-4. 2002
    ..This survey focuses on the individual definitions and treatment modalities of rheumatologists, and aims at determining the practical realisation of these concepts...
  80. pmc Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline
    D Aletaha
    Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 61:313-20. 2009
    ..To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity...
  81. pmc Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis
    V P K Nell
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Austria
    Ann Rheum Dis 64:1731-6. 2005
    ..Early treatment prevents progression of joint damage in rheumatoid arthritis (RA), but diagnosis in early disease is impeded by lack of appropriate diagnostic criteria...
  82. ncbi request reprint Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
    T Karonitsch
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1365-73. 2008
    ....
  83. ncbi request reprint Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease
    G Stacher
    Department of Surgery, University of Vienna, Austria
    J Rheumatol 27:692-7. 2000
    ..To study cardiovascular autonomic nerve function and presence of autoantibodies in relation to esophageal motor activity in patients with systemic sclerosis (SSc) and mixed connective tissue disease (MCTD)...
  84. pmc IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases
    L Kazemi-Shirazi
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Austria
    Clin Exp Immunol 128:102-9. 2002
    ..Our data indicate immunopathogenic similarities between IBD and CTD...
  85. ncbi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 59:1371-7. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  86. ncbi request reprint Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention
    M Aringer
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Lupus 13:344-7. 2004
    ..Interferon (IFN)-gamma, interleukin (IL)-18, IL-6 and possibly IL-1 are increased in SLE and likewise involved in the inflammatory process. Specific therapeutic agents for blocking these cytokines should be available in the near future...
  87. pmc Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency
    M D Köller
    Department Internal Medicine III, Division of Rheumatology, University of Vienna, Austria
    Clin Exp Immunol 132:225-31. 2003
    ..Despite the lack of proliferation, preactivated Tc phenotypically maintain an intermediate stage of activation. These data show how the same cell population can change its functional phenotype into a non-responder state...
  88. ncbi request reprint Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha
    K Redlich
    University of Vienna, Austria
    Arthritis Rheum 44:266-74. 2001
    ....
  89. ncbi request reprint Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 67:238-43. 2008
    ....
  90. pmc The "X-Ray RheumaCoach" software: a novel tool for enhancing the efficacy and accelerating radiological quantification in rheumatoid arthritis
    M Wick
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 62:579-82. 2003
    ..Precise diagnosis and follow up treatment of rheumatoid arthritis (RA) requires objective quantification, which is still lacking. For this purpose, radiological analyses are considered to be the most appropriate method...
  91. ncbi request reprint Serum interleukin-15 is elevated in systemic lupus erythematosus
    M Aringer
    Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
    Rheumatology (Oxford) 40:876-81. 2001
    ..Both lymphocyte CD25 and Bcl-2 expression significantly correlated with serum IL-15 and were increased by recombinant IL-15. CONCLUSION: Serum IL-15 may in part be responsible for the immunological abnormalities seen in active SLE...
  92. ncbi request reprint Advances in anti-inflammatory therapy
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna
    Acta Med Austriaca 29:1-6. 2002
    ..NSAIDs have the potential to cause adverse events in the GI tract. Therapy with histamine antagonists or sucralfate did not reduce the patients' rate of gastrointestinal adverse events...
  93. ncbi request reprint Functional and health status assessment in patients with rheumatoid arthritis
    Tanja A Stamm
    Department of Rheumatology, Division of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna
    Acta Med Austriaca 29:30-2. 2002
    ..These data are used to supplement the rheumatologist's decision about medical management of the disease and about further therapeutic strategies...
  94. pmc IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study
    G H Stummvoll
    Department of Rheumatology, Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 64:1015-21. 2005
    ....
  95. ncbi request reprint Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1-A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in mice
    G Steiner
    Department of Internal Medicine III, University of Vienna, Austria
    Clin Exp Rheumatol 20:517-24. 2002
    ..The aim of the present study was to evaluate the immune response and pathological features induced in mice immunized with anti-RA33 antibodies or patient-derived recombinant single-chain variable fragments (scFv) of anti-RA33 antibodies...
  96. ncbi request reprint Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
    V P K Nell
    Department of Rheumatology, Internal Medicine III, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheumatology (Oxford) 43:906-14. 2004
    ..We wanted to test if a therapeutic window of opportunity may exist within the first few months of the disease...
  97. ncbi request reprint Glucocorticoid treatment in rheumatoid arthritis: low-dose therapy does not reduce responsiveness to higher doses
    J Wolf
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 26:113-6. 2008
    ..Since low dose GC has been suggested to confer resistance to higher doses, we aimed to assess if resistance was detectable on the clinical level in patients with active RA...
  98. ncbi request reprint Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis
    M Bonelli
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, General Hospital of Vienna, Austria
    Ann Rheum Dis 67:664-71. 2008
    ..This tempted us to evaluate the significance of Foxp3 expression under autoimmune conditions with chronic T cell activation in patients with systemic lupus erythematosus (SLE) as compared with healthy controls (HCs)...
  99. doi request reprint Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus
    G H Stummvoll
    G Steiner, Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Ann Rheum Dis 68:110-6. 2009
    ....
  100. ncbi request reprint TNFalpha mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF1/hsp70 stress response
    G Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Cell Death Differ 10:1126-36. 2003
    ..The price of inhibition of an essential cellular stress response is increased sensitivity to apoptotic cell death...
  101. doi request reprint Treg and lupus
    M Bonelli
    Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 69:i65-66. 2010
    ..Advances in our understanding of how to characterise and manipulate Treg in patients with autoimmune diseases are required in order to develop new therapeutic strategies...